<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02802540</url>
  </required_header>
  <id_info>
    <org_study_id>NABILONA</org_study_id>
    <nct_id>NCT02802540</nct_id>
  </id_info>
  <brief_title>Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients</brief_title>
  <official_title>Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Patients With Anorexia Associated With Advanced Lung Cancer: Randomized Double Blind Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cancerologia de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cancerologia de Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anorexia is common symptom in cancer patients and is associated with increased morbidity and
      mortality. However timely detection with objective tools is necessary to establish the
      diagnosis of anorexia and to assess the magnitude of change over time. The anorexia
      pathophysiology is not clearly understood and treatment options are limited. Anecdotal
      historical benefits of smoking marijuana on nausea, pain and anorexia led to studies with
      marijuana and synthetic cannabinoids from Δ-9-tetrahydrocannabinol, the main active agent in
      marijuana. The endogenous cannabinoid system with its receptors CB1 and CB2 regulate appetite
      in four functional levels: (1) limbic system (hedonistic quality), (2) hypothalamus (appetite
      stimulant), (3) intestinal, and (4) tissue adipose.

      Nabilone, a synthetic analogue of THC approved in Mexico for nausea and vomiting induced by
      chemotherapy is also used in palliative care units for clinical improvement in increased
      appetite patients in terminal stages, however, there are no clinical trials demonstrating
      this benefit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Lung cancer is the leading cause of cancer death in Mexico and the world.
      Malnutrition is often associated with this type of cancer appearing in about 40-50% of
      patients the diagnosis made, affecting the quality of life and prognosis, as well as
      increased toxicity to cancer treatment. Cancer anorexia is characterized by loss of appetite
      and is the main cause of reduced food consumption in lung cancer patients. Anorexia occurs in
      up to 25% of cases. Unfortunately, current therapies available to treat anorexia and / or
      cachexia associated with cancer provide only partial results, mainly because the intervention
      is delayed and the development of an early and effective intervention is still looking.

      In most patients, malnutrition is associated with a hyporexia secondary to the production of
      pro-inflammatory cytokines such as tumor necrosis factor (TNF), leading to an increase in
      metabolism and appetite loss. Nabilone is a synthetic cannabinoid derivative that is widely
      used in oncology for its antiemetic and adjuvant effect of pain. Although widely used for the
      treatment of anorexia in palliative care, no randomized clinical trials demonstrating an
      effect on cancer-associated anorexia, however, in animal models, stimulation of cannabinoid
      receptors, mainly through CB1 receptor can modulate hypothalamic circuits in the brain stem,
      which in turn regulate food intake and satiety. Moreover cannabinoids are able to block the
      effects of TNF in the nervous system, which is associated with appetite changes in cancer
      patients. Additionally, agonists of cannabinoid receptors attenuated weight loss in murine
      models of anorexia.

      Additionally, to diagnosis anorexia The Anorexia-Cachexia scale (A/CS-12) from The Functional
      Assessment of Anorexia-Cachexia therapy (FAACT) questionnaire relates differences in symptoms
      and severity, assigning a value of 0-4 for each of 12 items. A 2010 consensus of special
      interest group of CACS from ESPEN (The European Society for Clinical Nutrition and
      Metabolism) in order to unify criteria, proposed that a score ≤24 of the A/CS-12 would be
      enough to establish a diagnosis of anorexia.

      The administration of Nabilone in patients with anorexia associated with Non-Small Cell Lung
      Cancer (NSCLC) is expected to increase appetite, nutritional status and quality of life.

      Methods: randomized double-blind clinical trial assessing Nabilone effect in non-small cell
      lung cancer (NSCLC) patients with unresectable stage III/IV NSCLC, ECOG performance status
      (ECOG PS) 1-2 and anorexia (main criteria: score of Anorexia Cachexia scale (AC/S-12) from
      Functional Assessment of Anorexia Cachexia Therapy ≤24). Patients are randomized to Nabilone
      at 0.5mg to 1mg, or placebo, given daily orally for 8 weeks. Changes are evaluated from
      baseline to week 2, 4, and 8.

      Time Assessment Dose T0 Baseline 0.5mg T1 2 weeks 1 mg T2 4 weeks 1 mg T3 8 weeks 1 mg

      Sample size:

      To determine the sample size is considered the effect of cannabinoid (dronabinol, 2.5 mg / 22
      days) in appetite in cancer patients by a difference in proportions of 34% more than placebo,
      requiring 32 patients per group plus 20% of loss gives us a total of 39 patients per group,
      with a power of 90% and an α of 0.05
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>anorexia</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>Lack of desire to eat food. Will be obtained through a questionnaire Anorexia / Cachexia scale from Functional Assessment of Anorexia Cachexia Therapy (FAACT) (score ≤24 diagnosis of anorexia)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>percentage weight loss</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>percentage weight loss in the last month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>It is an index of a person's weight in relation to height</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Global Assessment</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>convenient, fast and cheaper method used to make a nutritional assessment, consisting of 3 parts: anamnesis, physical examination and qualification.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>energy consumption</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>Total calories consumed on average per day for a subject</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>protein consumption</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>Total protein grams consumed on average per day for a subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipids consumption</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>Total lipids grams consumed on average per day for a subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carbohydrate consumption</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>Total carbohydrate grams consumed on average per day for a subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nausea</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>adverse effect from Common terminology criteria for adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vomiting</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>adverse effect from Common terminology criteria for adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>constipation</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>adverse effect from Common terminology criteria for adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diarrhea</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>adverse effect from Common terminology criteria for adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dysgeusia</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>adverse effect from Common terminology criteria for adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Status of Quality of Life</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>The Global status of Quality of Life evaluation is evaluated using the validated Mexican-Spanish version of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires specific for cancer with the items 29 and 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical functioning</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>The Physical functioning evaluation is evaluated from the validated Mexican-Spanish version of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires specific for cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role Functioning</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>The Role functioning evaluation is evaluated from the validated Mexican-Spanish version of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires specific for cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotional Functioning</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>The Emotional Functioning evaluation is evaluated from the validated Mexican-Spanish version of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires specific for cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Functioning</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>The Social Functioning evaluation is evaluated from the validated Mexican-Spanish version of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires specific for cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea/Vomiting</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>The Nausea/Vomiting evaluation is evaluated from the validated Mexican-Spanish version of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires specific for cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>The Fatigue evaluation is evaluated from the validated Mexican-Spanish version of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires specific for cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>appetite loss</measure>
    <time_frame>from the start of consumption until 8 weeks.</time_frame>
    <description>The appetite loss evaluation is evaluated from the validated Mexican-Spanish version of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires specific for cancer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Anorexia</condition>
  <condition>Cachexia</condition>
  <condition>Weight Lose</condition>
  <arm_group>
    <arm_group_label>Nabilone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients start receiving a dose of 0.5 mg daily oral nabilone the first 2 weeks and then 1 mg to complete 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients start receiving a dose of 0.5 mg daily oral placebo the first 2 weeks and then 1 mg to complete 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nabilone</intervention_name>
    <description>Patients going to take 0.5 mg capsules of nabilone (CESAMET) the first 2 weeks and then increased to 1 mg to complete 8 weeks.</description>
    <arm_group_label>Nabilone</arm_group_label>
    <other_name>cesamet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients going to take capsules of placebo until complete 8 weeks.</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>placebo nabilona</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-small cell lung cancer (NSCLC) patients with unresectable stage IIIB/IV

          -  ECOG performance status ≤2

          -  Life expectancy of &gt; 4 months at time of screening

          -  If woman of childbearing potential or a fertile man, he/she must agree to use an
             effective form of contraception during the study and for 30 days following the last
             dose of study drug (an effective form of contraception is abstinence, a hormonal
             contraceptive, or a double-barrier method)

          -  Must be willing and able to give signed informed consent and, in the opinion of the
             Investigator, to comply with the protocol tests and procedures

        Exclusion Criteria:

          -  Known allergy to some derivative of marijuana, there is a dependency or who have
             previously been treated with cannabinoids.

          -  Consumption of dietary supplements at baseline.

          -  Currently taking prescription medications intended to increase appetite or treat
             weight loss; these include, but are not limited to, testosterone, androgenic
             compounds, megestrol acetate, methylphenidate, and Anamorelin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar Arrieta, MD M Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Cancerología</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oscar Arrieta, MD M Sc</last_name>
    <phone>015556280400</phone>
    <phone_ext>71100</phone_ext>
    <email>ogarrieta@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diana Flores</last_name>
    <phone>015556280400</phone>
    <phone_ext>71101</phone_ext>
    <email>clinicacancerpulmonincan@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Arrieta</last_name>
      <phone>015556280400</phone>
      <email>ogarrieta@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.</citation>
    <PMID>25220842</PMID>
  </reference>
  <reference>
    <citation>Samet JM. Environmental causes of lung cancer: what do we know in 2003? Chest. 2004 May;125(5 Suppl):80S-3S.</citation>
    <PMID>15136426</PMID>
  </reference>
  <reference>
    <citation>Arrieta O, Campos-Parra AD, Zuloaga C, Avilés A, Sánchez-Reyes R, Manríquez ME, Covián-Molina E, Martínez-Barrera L, Meneses A, Cardona A, Borbolla-Escoboza JR. Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure. J Thorac Oncol. 2012 Aug;7(8):1228-34. doi: 10.1097/JTO.0b013e3182582a93.</citation>
    <PMID>22659961</PMID>
  </reference>
  <reference>
    <citation>Watanabe H, Yamamoto N, Tamura T, Shimoyama T, Hotta K, Inoue A, Sawada M, Akiyama Y, Kusaba H, Nokihara H, Sekine I, Kunitoh H, Ohe Y, Kodama T, Saijo N. Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol. 2003 Dec;33(12):626-30.</citation>
    <PMID>14769840</PMID>
  </reference>
  <reference>
    <citation>Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR; American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004 Jan 15;22(2):330-53. Epub 2003 Dec 22. Review.</citation>
    <PMID>14691125</PMID>
  </reference>
  <reference>
    <citation>Sarhill N, Mahmoud FA, Christie R, Tahir A. Assessment of nutritional status and fluid deficits in advanced cancer. Am J Hosp Palliat Care. 2003 Nov-Dec;20(6):465-73. Review.</citation>
    <PMID>14649565</PMID>
  </reference>
  <reference>
    <citation>Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G, Serna-Thomé MG, Flores-Estrada D, Diaz-Romero C, Rodríguez CM, Martínez L, Sánchez-Lara K. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer. 2010 Feb 21;10:50. doi: 10.1186/1471-2407-10-50.</citation>
    <PMID>20170547</PMID>
  </reference>
  <reference>
    <citation>Sánchez-Lara K, Turcott JG, Juárez E, Guevara P, Núñez-Valencia C, Oñate-Ocaña LF, Flores D, Arrieta O. Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study. Nutr Cancer. 2012;64(4):526-34. doi: 10.1080/01635581.2012.668744. Epub 2012 Apr 10.</citation>
    <PMID>22489794</PMID>
  </reference>
  <reference>
    <citation>Bossola M, Pacelli F, Doglietto GB. Novel treatments for cancer cachexia. Expert Opin Investig Drugs. 2007 Aug;16(8):1241-53. Review.</citation>
    <PMID>17685872</PMID>
  </reference>
  <reference>
    <citation>Wie GA, Cho YA, Kim SY, Kim SM, Bae JM, Joung H. Prevalence and risk factors of malnutrition among cancer patients according to tumor location and stage in the National Cancer Center in Korea. Nutrition. 2010 Mar;26(3):263-8. doi: 10.1016/j.nut.2009.04.013. Epub 2009 Aug 8.</citation>
    <PMID>19665873</PMID>
  </reference>
  <reference>
    <citation>Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, Smith IE, O'Brien ME. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer. 2004 May 17;90(10):1905-11.</citation>
    <PMID>15138470</PMID>
  </reference>
  <reference>
    <citation>Slaviero KA, Read JA, Clarke SJ, Rivory LP. Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy. Nutr Cancer. 2003;46(2):148-57.</citation>
    <PMID>14690790</PMID>
  </reference>
  <reference>
    <citation>Muscaritoli M, Anker SD, Argilés J, Aversa Z, Bauer JM, Biolo G, Boirie Y, Bosaeus I, Cederholm T, Costelli P, Fearon KC, Laviano A, Maggio M, Rossi Fanelli F, Schneider SM, Schols A, Sieber CC. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) &quot;cachexia-anorexia in chronic wasting diseases&quot; and &quot;nutrition in geriatrics&quot;. Clin Nutr. 2010 Apr;29(2):154-9. doi: 10.1016/j.clnu.2009.12.004. Epub 2010 Jan 8.</citation>
    <PMID>20060626</PMID>
  </reference>
  <reference>
    <citation>Marín Caro MM, Laviano A, Pichard C. Impact of nutrition on quality of life during cancer. Curr Opin Clin Nutr Metab Care. 2007 Jul;10(4):480-7. Review.</citation>
    <PMID>17563467</PMID>
  </reference>
  <reference>
    <citation>Kosacka M, Weryńska B, Gołecki M, Jankowska R, Passowicz-Muszyńska E. [The incidence and pathogenesis of cancer anorexia-cachexia syndrome in lung cancer]. Pneumonol Alergol Pol. 2008;76(5):360-5. Review. Polish.</citation>
    <PMID>19003767</PMID>
  </reference>
  <reference>
    <citation>Fortunati N, Manti R, Birocco N, Pugliese M, Brignardello E, Ciuffreda L, Catalano MG, Aragno M, Boccuzzi G. Pro-inflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients. Oncol Rep. 2007 Dec;18(6):1521-7.</citation>
    <PMID>17982639</PMID>
  </reference>
  <reference>
    <citation>Jatoi A, Qi Y, Kendall G, Jiang R, McNallan S, Cunningham J, Mandrekar S, Yang P. The cancer anorexia/weight loss syndrome: exploring associations with single nucleotide polymorphisms (SNPs) of inflammatory cytokines in patients with non-small cell lung cancer. Support Care Cancer. 2010 Oct;18(10):1299-304. doi: 10.1007/s00520-009-0748-6. Epub 2009 Dec 15.</citation>
    <PMID>20012999</PMID>
  </reference>
  <reference>
    <citation>Laviano A, Meguid MM, Inui A, Muscaritoli M, Rossi-Fanelli F. Therapy insight: Cancer anorexia-cachexia syndrome--when all you can eat is yourself. Nat Clin Pract Oncol. 2005 Mar;2(3):158-65. Review.</citation>
    <PMID>16264909</PMID>
  </reference>
  <reference>
    <citation>Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO Jr, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980 Oct;69(4):491-7.</citation>
    <PMID>7424938</PMID>
  </reference>
  <reference>
    <citation>Laviano A, Koverech A, Mari A. Cachexia: clinical features when inflammation drives malnutrition. Proc Nutr Soc. 2015 Nov;74(4):348-54. doi: 10.1017/S0029665115000117. Epub 2015 Mar 26. Review.</citation>
    <PMID>25809872</PMID>
  </reference>
  <reference>
    <citation>Argilés JM, Busquets S, López-Soriano FJ. The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol. 2005 Oct;37(10):2036-46. Review.</citation>
    <PMID>16105746</PMID>
  </reference>
  <reference>
    <citation>Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 2005 May;8(3):265-9. Review.</citation>
    <PMID>15809528</PMID>
  </reference>
  <reference>
    <citation>LeBlanc TW, Samsa GP, Wolf SP, Locke SC, Cella DF, Abernethy AP. Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS). Support Care Cancer. 2015 Aug;23(8):2341-7. doi: 10.1007/s00520-015-2606-z. Epub 2015 Jan 14.</citation>
    <PMID>25586527</PMID>
  </reference>
  <reference>
    <citation>Gupta D, Lammersfeld CA, Vashi PG, King J, Dahlk SL, Grutsch JF, Lis CG. Bioelectrical impedance phase angle in clinical practice: implications for prognosis in stage IIIB and IV non-small cell lung cancer. BMC Cancer. 2009 Jan 28;9:37. doi: 10.1186/1471-2407-9-37.</citation>
    <PMID>19175932</PMID>
  </reference>
  <reference>
    <citation>Kubrak C, Jensen L. Critical evaluation of nutrition screening tools recommended for oncology patients. Cancer Nurs. 2007 Sep-Oct;30(5):E1-6. Review.</citation>
    <PMID>17876173</PMID>
  </reference>
  <reference>
    <citation>Hernández-Avila M, Romieu I, Parra S, Hernández-Avila J, Madrigal H, Willett W. Validity and reproducibility of a food frequency questionnaire to assess dietary intake of women living in Mexico City. Salud Publica Mex. 1998 Mar-Apr;40(2):133-40.</citation>
    <PMID>9617194</PMID>
  </reference>
  <reference>
    <citation>Thoresen L, Fjeldstad I, Krogstad K, Kaasa S, Falkmer UG. Nutritional status of patients with advanced cancer: the value of using the subjective global assessment of nutritional status as a screening tool. Palliat Med. 2002 Jan;16(1):33-42.</citation>
    <PMID>11963449</PMID>
  </reference>
  <reference>
    <citation>Berry EM, Mechoulam R. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther. 2002 Aug;95(2):185-90. Review.</citation>
    <PMID>12182965</PMID>
  </reference>
  <reference>
    <citation>Touw M. The religious and medicinal uses of Cannabis in China, India and Tibet. J Psychoactive Drugs. 1981 Jan-Mar;13(1):23-34. Review.</citation>
    <PMID>7024492</PMID>
  </reference>
  <reference>
    <citation>Davis MP. Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs. 2008 Jan;17(1):85-95. Review.</citation>
    <PMID>18095921</PMID>
  </reference>
  <reference>
    <citation>Osei-Hyiaman D. Endocannabinoid system in cancer cachexia. Curr Opin Clin Nutr Metab Care. 2007 Jul;10(4):443-8. Review.</citation>
    <PMID>17563462</PMID>
  </reference>
  <reference>
    <citation>Pisanti S, Malfitano AM, Grimaldi C, Santoro A, Gazzerro P, Laezza C, Bifulco M. Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):117-31. doi: 10.1016/j.beem.2009.02.001. Review.</citation>
    <PMID>19285265</PMID>
  </reference>
  <reference>
    <citation>Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, Járai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001 Apr 12;410(6830):822-5.</citation>
    <PMID>11298451</PMID>
  </reference>
  <reference>
    <citation>Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer. 2003 Mar;11(3):137-43. Epub 2002 Aug 21. Review.</citation>
    <PMID>12618922</PMID>
  </reference>
  <reference>
    <citation>Kramer JL. Medical marijuana for cancer. CA Cancer J Clin. 2015 Mar;65(2):109-22. doi: 10.3322/caac.21260. Epub 2014 Dec 10. Review.</citation>
    <PMID>25503438</PMID>
  </reference>
  <results_reference>
    <citation>Cannabis-In-Cachexia-Study-Group, Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol. 2006 Jul 20;24(21):3394-400.</citation>
    <PMID>16849753</PMID>
  </results_reference>
  <results_reference>
    <citation>Foltin RW, Brady JV, Fischman MW. Behavioral analysis of marijuana effects on food intake in humans. Pharmacol Biochem Behav. 1986 Sep;25(3):577-82.</citation>
    <PMID>3774823</PMID>
  </results_reference>
  <results_reference>
    <citation>Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol. Pharmacol Biochem Behav. 1991 Nov;40(3):695-700. Review.</citation>
    <PMID>1666930</PMID>
  </results_reference>
  <results_reference>
    <citation>Nelson K, Walsh D, Deeter P, Sheehan F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care. 1994 Spring;10(1):14-8. Review.</citation>
    <PMID>8035251</PMID>
  </results_reference>
  <results_reference>
    <citation>Hart CL, Ward AS, Haney M, Comer SD, Foltin RW, Fischman MW. Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans. Psychopharmacology (Berl). 2002 Dec;164(4):407-15. Epub 2002 Sep 14.</citation>
    <PMID>12457271</PMID>
  </results_reference>
  <results_reference>
    <citation>Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002 Jan 15;20(2):567-73.</citation>
    <PMID>11786587</PMID>
  </results_reference>
  <results_reference>
    <citation>Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage. 2005 Apr;29(4):358-67.</citation>
    <PMID>15857739</PMID>
  </results_reference>
  <results_reference>
    <citation>Haney M, Rabkin J, Gunderson E, Foltin RW. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology (Berl). 2005 Aug;181(1):170-8. Epub 2005 Oct 15.</citation>
    <PMID>15778874</PMID>
  </results_reference>
  <results_reference>
    <citation>Walsh D, Kirkova J, Davis MP. The efficacy and tolerability of long-term use of dronabinol in cancer-related anorexia: a case series. J Pain Symptom Manage. 2005 Dec;30(6):493-5.</citation>
    <PMID>16376734</PMID>
  </results_reference>
  <results_reference>
    <citation>Zutt M, Hänssle H, Emmert S, Neumann C, Kretschmer L. [Dronabinol for supportive therapy in patients with malignant melanoma and liver metastases]. Hautarzt. 2006 May;57(5):423-7. German.</citation>
    <PMID>16408219</PMID>
  </results_reference>
  <results_reference>
    <citation>Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin RW. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J Acquir Immune Defic Syndr. 2007 Aug 15;45(5):545-54.</citation>
    <PMID>17589370</PMID>
  </results_reference>
  <results_reference>
    <citation>Maida V, Ennis M, Irani S, Corbo M, Dolzhykov M. Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. J Support Oncol. 2008 Mar;6(3):119-24.</citation>
    <PMID>18402303</PMID>
  </results_reference>
  <results_reference>
    <citation>Brisbois TD, de Kock IH, Watanabe SM, Mirhosseini M, Lamoureux DC, Chasen M, MacDonald N, Baracos VE, Wismer WV. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol. 2011 Sep;22(9):2086-93. doi: 10.1093/annonc/mdq727. Epub 2011 Feb 22.</citation>
    <PMID>21343383</PMID>
  </results_reference>
  <results_reference>
    <citation>Rowland KM Jr, Loprinzi CL, Shaw EG, Maksymiuk AW, Kuross SA, Jung SH, Kugler JW, Tschetter LK, Ghosh C, Schaefer PL, Owen D, Washburn JH Jr, Webb TA, Mailliard JA, Jett JR. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol. 1996 Jan;14(1):135-41.</citation>
    <PMID>8558188</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cancerologia de Mexico</investigator_affiliation>
    <investigator_full_name>Oscar Gerardo Arrieta Rodríguez MD</investigator_full_name>
    <investigator_title>MD M Sc</investigator_title>
  </responsible_party>
  <keyword>nabilone</keyword>
  <keyword>anorexia</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nabilone</mesh_term>
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>publishing the results</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

